OBJECT: Haptoglobin allele heterogeneity has been implicated in differential reactive oxidant inhibition and inflammation. Haptoglobin α2-α2 has a lower affinity for binding hemoglobin, and when bound to hemoglobin, is cleared less easily by the body. The authors hypothesized that haptoglobin α2-α2 genotype should be less protective for downstream injury after aneurysmal subarachnoid hemorrhage (aSAH) and should portend a worse outcome. METHODS: Patients with Fisher Grade 2 or higher aSAH were enrolled in the study. Genotyping for haptoglobin genotype was performed from blood and/or CSF. Demographic information, medical condition variables, and hospital course were abstracted from the medical record upon enrollment into the study. Outcome data (modified Rankin Scale score, Glasgow Outcome Scale score, and mortality) were collected at 3 months posthemorrhage. RESULTS: The authors enrolled 193 patients who ranged in age from 18 to 75 years. Only Caucasians were used in this analysis to minimize bias from variable haptoglobin allele frequencies in populations of different ancestral backgrounds. The sample had more women than men (overall mean age 54.45 years). Haptoglobin α2 homozygotes were older than the other individuals in the study sample (57.27 vs 53.2 years, respectively; p = 0.02) and were more likely to have Fisher Grade 3 SAH (p = 0.02). Haptoglobin α2-α2 genotype, along with Fisher grade and Hunt and Hess grade, was associated with a worse 3-month outcome compared to those with the haptoglobin α1-α1 genotype according to modified Rankin Scale score after controlling for covariates (OR 4.138, p = 0.0463). CONCLUSIONS: Patients with aSAH who carry the haptoglobin α2-α2 genotype had a worse outcome. Interestingly, the presence of a single α-2 allele was associated with worse outcome, suggesting that the haptoglobin α-2 protein may play a role in the pathology of brain injury following aSAH, although the mechanism for this finding requires further research. The haptoglobin genotype may provide additional information on individual risk of secondary injury and recovery to guide care focused on improving outcomes.
OBJECT: Haptoglobin allele heterogeneity has been implicated in differential reactive oxidant inhibition and inflammation. Haptoglobin α2-α2 has a lower affinity for binding hemoglobin, and when bound to hemoglobin, is cleared less easily by the body. The authors hypothesized that haptoglobin α2-α2 genotype should be less protective for downstream injury after aneurysmal subarachnoid hemorrhage (aSAH) and should portend a worse outcome. METHODS:Patients with Fisher Grade 2 or higher aSAH were enrolled in the study. Genotyping for haptoglobin genotype was performed from blood and/or CSF. Demographic information, medical condition variables, and hospital course were abstracted from the medical record upon enrollment into the study. Outcome data (modified Rankin Scale score, Glasgow Outcome Scale score, and mortality) were collected at 3 months posthemorrhage. RESULTS: The authors enrolled 193 patients who ranged in age from 18 to 75 years. Only Caucasians were used in this analysis to minimize bias from variable haptoglobin allele frequencies in populations of different ancestral backgrounds. The sample had more women than men (overall mean age 54.45 years). Haptoglobin α2 homozygotes were older than the other individuals in the study sample (57.27 vs 53.2 years, respectively; p = 0.02) and were more likely to have Fisher Grade 3 SAH (p = 0.02). Haptoglobin α2-α2 genotype, along with Fisher grade and Hunt and Hess grade, was associated with a worse 3-month outcome compared to those with the haptoglobin α1-α1 genotype according to modified Rankin Scale score after controlling for covariates (OR 4.138, p = 0.0463). CONCLUSIONS:Patients with aSAH who carry the haptoglobin α2-α2 genotype had a worse outcome. Interestingly, the presence of a single α-2 allele was associated with worse outcome, suggesting that the haptoglobin α-2 protein may play a role in the pathology of brain injury following aSAH, although the mechanism for this finding requires further research. The haptoglobin genotype may provide additional information on individual risk of secondary injury and recovery to guide care focused on improving outcomes.
Authors: Werner Koch; Wolfgang Latz; Marianne Eichinger; Ariel Roguin; Andrew P Levy; Albert Schömig; Adnan Kastrati Journal: Clin Chem Date: 2002-09 Impact factor: 8.327
Authors: Jenna L Leclerc; Spiros Blackburn; Dan Neal; Nicholas V Mendez; Jeffrey A Wharton; Michael F Waters; Sylvain Doré Journal: Proc Natl Acad Sci U S A Date: 2015-01-12 Impact factor: 11.205
Authors: V Eric Kerchberger; Julie A Bastarache; Ciara M Shaver; Hiromasa Nagata; J Brennan McNeil; Stuart R Landstreet; Nathan D Putz; Wen-Kuang Yu; Jordan Jesse; Nancy E Wickersham; Tatiana N Sidorova; David R Janz; Chirag R Parikh; Edward D Siew; Lorraine B Ware Journal: JCI Insight Date: 2019-11-01
Authors: Ben Gaastra; Dianxu Ren; Sheila Alexander; Ellen R Bennett; Dawn M Bielawski; Spiros L Blackburn; Mark K Borsody; Sylvain Doré; James Galea; Patrick Garland; Tian He; Koji Iihara; Yoichiro Kawamura; Jenna L Leclerc; James F Meschia; Michael A Pizzi; Rafael J Tamargo; Wuyang Yang; Paul A Nyquist; Diederik O Bulters; Ian Galea Journal: Neurology Date: 2019-04-05 Impact factor: 9.910
Authors: Josephine A D'Abbondanza; Jinglu Ai; Elliot Lass; Hoyee Wan; Shakira Brathwaite; Michael K Tso; Charles Lee; Philip A Marsden; R Loch Macdonald Journal: J Cereb Blood Flow Metab Date: 2015-10-26 Impact factor: 6.200
Authors: Matthew J Morton; Isabel C Hostettler; Nabila Kazmi; Varinder S Alg; Stephen Bonner; Martin M Brown; Andrew Durnford; Benjamin Gaastra; Patrick Garland; Joan Grieve; Neil Kitchen; Daniel Walsh; Ardalan Zolnourian; Henry Houlden; Tom R Gaunt; Diederik O Bulters; David J Werring; Ian Galea Journal: J Neurol Neurosurg Psychiatry Date: 2020-01-14 Impact factor: 10.154